# US 2024/0043372 A1 · Substituted aromatic compounds and pharmaceutical compositions thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0043372 A1
- Document ID: US20240043372A1
- Status: Published application
- Kind: A1
- Application number: 18/245,695
- Filed: 2021-10-05
- Published: 2024-02-08
- Earliest claimed: 2020-10-06
- Assignees: Pharmaceutique Ingenew Inc.
- Applicants: Pharmaceutique Ingenew Inc.
- Inventors: Lyne GAGNON
- Web page: https://patentgrep.com/patent/US20240043372A1

## CPC

- C07C 235/34: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 35/00: Antineoplastic agents
- C07C 33/20: monocyclic
- C07C 39/11: Alkylated hydroxy benzenes containing also acyclically bound hydroxy groups, e.g. saligenol
- C07C 43/178: containing hydroxy or O-metal groups
- C07C 47/27: containing six-membered aromatic rings
- C07C 49/245: containing six-membered aromatic rings
- C07C 59/52: a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
- C07C 215/68: having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C 2601/02: with a three-membered ring
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of Formula I or II, methods of preparation and of use thereof. Formula I has a core aromatic group with substituents as follows: Formula (I) wherein G1 is —(CH2)nC(R1)(R2)OH, —(CH2)n; —CHO, —(CH2)nC(O)NR1R2, —(CH2)nCH (R1)NR1R2, —(CH2)nC(O)OR3, —(CH2)n—CH(R1)O—R3, or —(CH2)nC(O)R3; G2 and G4 are independently H, OH, F, or Cl, where G2 can also be NH2; G3 and G5 are independently (H, F, Cl, OH, —(CH2)n-optionally substituted heterocycle, —(CH2)n-optionally substituted phenyl, —(CH2)nC3H5, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, —C(O)—R3, or CH(OH)—R3; and G6 is H, F, Cl, OH, —(CH2)n-optionally substituted heterocycle, —(CH2)n-optionally substituted phenyl, or (CH2)nCOOH, wherein ⋅n is an integer selected from 0 to 5, ⋅R1 and R2 are independently selected from H and optionally substituted C1-C6 alkyl group, and ⋅R3 is an optionally substituted C1-C6 alkyl group or when present on G1 forms a lactone with the core aromatic group, or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound according to Formula I having a core aromatic group with substituents as follows:
wherein
G1 is —(CH2)nC(R1)(R2)OH, —(CH2)n—CHO, —(CH2)nC(O)NR1R2, —(CH2)nCH (R1)NR1R2, —(CH2)nC(O)OR3, —(CH2)n—CH(R1)O—R3, or —(CH2)nC(O)R3;
G2 is H, NH2, OH, F, or Cl;
G3 is H, F, Cl, OH, —(CH2)n-optionally substituted heterocycle, —(CH2)n-optionally substituted phenyl, —(CH2)nC3H5, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, —C(O)—R3, and CH(OH)—R3;
G4 is H, OH, F or Cl;
G5 is H, OH, F, Cl, —(CH2)n-optionally substituted heterocycle, —(CH2)n-optionally substituted phenyl, —(CH2)nC3H5, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, —C(O)—R3, or CH(OH)—R3; and
G6 is H, F, Cl, OH, —(CH2)n-optionally substituted heterocycle, or —(CH2)n-optionally substituted phenyl,
wherein
n is an integer selected from 0 to 5;
R1 and R2 are independently selected from H and optionally substituted C1-C6 alkyl group, and
R3 is an optionally substituted C1-C6 alkyl group or when present on G1 forms a lactone with the core aromatic group,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G3 is C5 alkyl, C5 alkenyl, —C(O)—(CH2)3—CH3 or —CH(OH)—(CH2)3—CH3.

### Claim 3 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1 wherein G3 is C6 alkyl, C6 alkenyl, —C(O)—(CH2)4—CH3 or —CH(OH)—(CH2)4—CH3.

### Claim 4 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G3 is C5 alkyl, C6 alkyl, C5 alkenyl, or C6 alkenyl.

### Claim 5 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G3 is C5 alkyl or C5 alkenyl.

### Claim 6 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G3 is C5 alkyl or C6 alkyl.

### Claim 7 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G3 is C5 alkyl.

### Claim 8 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G3 is —(CH2)n-optionally substituted phenyl.

### Claim 9 (depends on 8)

The compound or pharmaceutically acceptable salt thereof of claim 8, wherein the phenyl is substituted with an optionally substituted C1-C6 alkyl.

### Claim 10 (depends on 9)

The compound or pharmaceutically acceptable salt thereof of claim 9, wherein G3 is CH3(CH2)x—C6H4—(CH2)y— wherein x+y=4 or 5, and wherein y is an integer selected from 0 to 5.

### Claim 11 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G3 is —(CH2)n-optionally substituted heterocycle.

### Claim 12 (depends on 11)

The compound or pharmaceutically acceptable salt thereof of claim 11, wherein the heterocycle has from 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur.

### Claim 13 (depends on 11)

The compound or pharmaceutically acceptable salt thereof of claim 11, wherein the heterocycle is a non-aromatic monocyclic or polycyclic ring.

### Claim 14 (depends on 11)

The compound or pharmaceutically acceptable salt thereof of claim 11, wherein the heterocycle is an aromatic ring.

### Claim 15 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G5 is H, OH, F, —CH2Phe, —CH2—C3H5, C4-C6 alkyl, —(CH2)nCH═CH, or —CH═CH(CH2), wherein n is 2 or 3.

### Claim 16 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G1 is
—(CH2)nCH(CH3)OH;
—(CH2)n—CH2—O—CH3;
—(CH2)nCH(O)NH2;
—(CH2)nC(O)R3;
—C(CH3)2OH;
—CH(F)—OH;
—CF2—OH;
—C(O)CH3;
—CH2C(O)OR3; or
—(CH2)nC(O)R3;
or pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G1 is —(CH2)nC(R1)(R2)OH.

### Claim 18 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G1 is —(CH2)n—CHO.

### Claim 19 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G1 is —(CH2)nC(O)NR1R2.

### Claim 20 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G1 is —(CH2)nCH (R1)NR1R2.

### Claim 21 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G1 is —(CH2)nC(O)OR3.

### Claim 22 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G1 is —(CH2)n—CH(R1)O—R3.

### Claim 23 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein G1 is —(CH2)nC(O)R3.

### Claim 24 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound is:
2-(2-hydroxypropyl)-4,6-dipentylphenol;
4-benzyl-2-(2-hydroxypropyl)-6-pentylphenol;
2,4-dibenzyl-6-(2-hydroxypropyl)phenol;
2-benzyl-6-(2-hydroxypropyl)-4-pentylphenol;
2,4-bis(3-cyclopropylpropyl)-6-(2-hydroxypropyl)phenol;
2-(2-hydroxy-3,5-dipentylphenyl)acetamide;
2-(5-benzyl-2-hydroxy-3-pentylphenyl)acetamide;
2-(3,5-dibenzyl-2-hydroxyphenyl)acetamide;
2-(3-benzyl-2-hydroxy-5-pentylphenyl)acetamide;
2-(3,5-bis(3-cyclopropylpropyl)-2-hydroxyphenyl)acetamide;
2-(2-hydroxy-3,5-dipentylphenyl)acetaldehyde;
2-(5-benzyl-2-hydroxy-3-pentylphenyl)acetaldehyde;
2-(3,5-dibenzyl-2-hydroxyphenyl)acetaldehyde;
2-(3-benzyl-2-hydroxy-5-pentylphenyl)acetaldehyde;
2-(3,5-bis(3-cyclopropylpropyl)-2-hydroxyphenyl)acetaldehyde;
1-(2-hydroxy-3,5-dipentylphenyl)propan-2-one;
1-(5-benzyl-2-hydroxy-3-pentylphenyl)propan-2-one;
1-(3,5-dibenzyl-2-hydroxyphenyl)propan-2-one;
1-(3-benzyl-2-hydroxy-5-pentylphenyl)propan-2-one;
1-(3,5-bis(3-cyclopropylpropyl)-2-hydroxyphenyl)propan-2-one;
methyl 2-(2-hydroxy-3,5-dipentylphenyl)acetate;
methyl 2-(5-benzyl-2-hydroxy-3-pentylphenyl)acetate;
methyl 2-(3,5-dibenzyl-2-hydroxyphenyl)acetate;
methyl 2-(3-benzyl-2-hydroxy-5-pentylphenyl)acetate;
methyl 2-(3,5-bis(3-cyclopropylpropyl)-2-hydroxyphenyl)acetate;
2-(2-methoxypropyl)-4,6-dipentylphenol;
4-benzyl-2-(2-methoxypropyl)-6-pentylphenol;
2,4-dibenzyl-6-(2-methoxypropyl)phenol;
2-benzyl-6-(2-methoxypropyl)-4-pentylphenol; or
2,4-bis(3-cyclopropylpropyl)-6-(2-methoxypropyl)phenol,
or pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, which is:
or pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 1)

The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the pharmaceutically acceptable salt of said compound is an organic or inorganic salt.

### Claim 27 (depends on 26)

The compound or pharmaceutically acceptable salt thereof of claim 26, wherein the salt is a sodium, potassium, lithium, ammonium, calcium, magnesium, manganese, zinc, iron, or copper salt.

### Claim 28 (depends on 26)

The compound or pharmaceutically acceptable salt thereof of claim 26, wherein the salt is an acetate, benzoate, besylate, bromide, carbonate, citrate, edisylate, estolate, fumarate, gluconate, hippurate, iodide, maleate, mesylate, methylsulfate, napsylate, oxalate, pamoate, phosphate, stearate, succinate, sulfate, tartrate, tosylate, or chloride salt.

### Claim at position 29

-43. (canceled)

### Claim 44 (depends on 1)

A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutical acceptable carrier, diluent or carrier.

### Claim 45 (depends on 1)

A method for treatment or prevention of cancer, inflammatory-related disease, oxidative stress, pain, metabolic disorder or a fibrotic-related disease in a subject, comprising administering a therapeutically effective amount of the compound of claim 1 to the subject.

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48 (depends on 45)

The method of claim 45, wherein the treatment of cancer includes inhibition of tumor growth, cell proliferation, tumor cell migration or metastasis in a subject suffering from the cancer.

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52 (depends on 1, 45)

The method of claim 45, wherein the compound of claim 1 is administered in combination with an anticancer agent.

### Claim 53 (depends on 52)

The method of claim 52, wherein the anticancer agent is temozolomide, abraxane, decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, bleomycin, alectinib, melphalan, pamidronate, bevacizumab, carbozantinib, vinblastine, docetaxel, prednisolone, ifosphamide, dexamethasone, vincristine, bleomycin, etoposide, topotecan, mitomycine, irinotecan, taxotere, taxol, 5-fluorouracil, folfirinox, methotrexate, gemcitabine, cisplatin, carboplatin, chlorambucil, beribucin, or tyrosine kinase inhibitors.

### Claim 54 (depends on 45)

The method of claim 45, wherein the cancer is bladder cancer, breast cancer, colorectal cancer, kidney cancer, melanoma, non-Hodgkin's lymphoma, lung, liver, leukemia, glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer or uterine cancer.

### Claim 55 (depends on 45)

The method of claim 45, wherein the cancer is glioblastoma or melanoma, and wherein the compound is administered in combination with chitosan for in situ treatment of recurrence of cancer.

### Claim 56 (depends on 45)

The method of claim 45, for treating or preventing a fibrotic-related disease.

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60 (depends on 45)

The method of claim 45, wherein the subject is a human.
